Larry Suva, Ph.D. is Director of the Center for Orthopaedic Research at UAMS. He is well known internationally for his research and has a broad scientific background gathered from years in the pharmaceutical and biotechnology industry (Genentech Inc., Merck, GlaxoSmithKline), as well as five years on the faculty of Harvard Medical School. His research interests include the anabolic stimulation of bone formation, mechanical regulation on bone and cartilage function and the pathogenesis of breast cancer metastasis to bone.
Suva LJ, Gaddy D, Perrien DS, Thomas RL and Findlay DM. Regulation of Bone Mass by Mechanical Loading: Microarchitecture and Genetics. Current Osteoporosis Reports. 3:46-51, 2005
Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD and MacDougald, OA. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl. Acad. Sci. (U.S.A.). 102:3324-3329, 2005
Bendre MS, Margulies AG, Walser B, Akel NS , Bhattacharrya S , Skinner RA , Swain F , Ramani V , Mohammad KS , Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclearfactor-kappaB ligand pathway. Cancer Research 65:11001-11009, 2005
Lazarenko OP, Rzonca SO, Suva LJ, and Lecka-Czernik B. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 38:74-84, 2006
